Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome

Arun Cumpelik1, Barbara Ankli2, Daniel Zecher3

  • 1Department of Biomedicine, University Hospital Basel, Basel, Switzerland Department of Medicine, University Hospital Basel, Basel, Switzerland.

Abstract

Insights

Neutrophil-derived microvesicles (PMN-Ecto) suppress gout inflammation by inhibiting inflammasome activation. These microvesicles, found in gout patients, offer a novel mechanism for gout resolution.

Area of Science:

  • Immunology
  • Inflammation Research
  • Cell Biology

Background:

  • Gout is an inflammatory joint disease caused by monosodium urate (MSU) crystals.
  • Inflammasome activation by MSU crystals drives acute gout inflammation.
  • The mechanisms controlling gout's spontaneous resolution remain largely unknown.

Purpose of the Study:

  • To investigate the role of neutrophil-derived microvesicles (PMN-Ecto) in resolving acute gout inflammation.
  • To analyze the anti-inflammatory properties of PMN-Ecto in a murine model and in human gout patients.

Main Methods:

  • Murine model of MSU-induced peritonitis using wild-type, MerTK(-/-), and C5aR(-/-) mice.
  • Quantification of neutrophils, PMN-Ecto, cytokines (IL-1β, TGFβ), and complement factor C5a in the peritoneal compartment.
  • Isolation and in vitro functional testing of human PMN-Ecto from gout patients' joint aspirates.

Main Results:

  • MSU-induced C5a primed the inflammasome, leading to IL-1β release and neutrophil infiltration.
  • Phosphatidylserine (PS)-positive PMN-Ecto suppressed C5a priming of the inflammasome, reducing IL-1β release and neutrophil influx.
  • PMN-Ecto-mediated suppression required MerTK, and PMN-Ecto also triggered TGFβ release.
  • PMN-Ecto from gout patients exhibited similar anti-inflammatory effects.

Conclusions:

  • Neutrophil-derived microvesicles (PMN-Ecto) play a crucial role in the resolution of gout.
  • PMN-Ecto-mediated inflammasome control represents an autoregulatory mechanism initiated during neutrophil activation in gout.
  • These findings highlight PMN-Ecto as a potential therapeutic target for managing gout.